Cardiovascular Diseases in Obesity: What is the Role of Magnesium?

Overview

Journal Biol Trace Elem Res

Date 2021 Jan 3

PMID 33389619

Citations 6

Authors

Loanne Rocha Dos Santos

Stefany Rodrigues de Sousa Melo

Juliana Soares Severo

Jennifer Beatriz Silva Morais

Lyandra Dias da Silva

Mickael de Paiva Sousa

Thayanne Gabryelle Visgueira de Sousa

Gilberto Simeone Henriques

Dilina do Nascimento Marreiro

Affiliations

Soon will be listed here.

Abstract

An excess of adipose tissue, a characteristic of obesity, has been associated with endocrine-metabolic alterations that contribute to dyslipidemias, which are characterized by an increase in the plasma concentrations of triacylglycerols, total cholesterol, and LDL-c along with a reduction in HDL-c. Some nutrients such as the mineral magnesium play important roles in lipid metabolism. Magnesium regulates the activity of HMG-CoA reductase, increasing the activity of lipoprotein lipase and lecithin-cholesterol acyltransferase. The objective of this review is to present important aspects about the contribution of obesity to the manifestation of cardiovascular risk, to bring the main physiological functions of magnesium, as well as the role of the nutrient in the protection against cardiovascular diseases. Studies have shown that individuals with obesity have low intracellular concentrations of magnesium, which can compromise the nutrient's physiological functions. Thus, this mineral appears to play an important role in protecting against cardiovascular diseases; however, changes in the nutrient metabolism in obesity may compromise the functions of this element. Further studies are needed to clarify this.

Citing Articles

The effect of magnesium supplementation on serum concentration of lipid profile: an updated systematic review and dose-response meta-analysis on randomized controlled trials.

Hariri M, Sohrabi M, Gholami A Nutr J. 2025; 24(1):24.

PMID: 39905454 PMC: 11796098. DOI: 10.1186/s12937-025-01085-w.

Serum magnesium, not calcium, is inversely associated with abnormal HbA1c concentrations in adults with coronary artery disease.

Dong H, Lu N, Wang J, Hu P Asia Pac J Clin Nutr. 2025; 34(1):104-111.

PMID: 39828263 PMC: 11742607. DOI: 10.6133/apjcn.202502_34(1).0010.

Utilizing a Combination of Supplements Comprising Boric Acid, Magnesium, Vitamin D3, and Extra Virgin Olive Oil to Improve Metabolism in Menopausal Ovariectomized Rats.

Atteia H, Ahmed S, Askar M, Sakr A Biol Trace Elem Res. 2024; .

PMID: 39731655 DOI: 10.1007/s12011-024-04476-y.

Effects of 3021 meal replacement powder protect NAFLD via suppressing the ERS, oxidative stress and inflammatory responses.

Xie Q, Gao S, Li Y, Xi W, Dong Z, Li Z PeerJ. 2023; 11:e16154.

PMID: 37868068 PMC: 10586295. DOI: 10.7717/peerj.16154.

The association between lipid profile, oxidized LDL and the components of metabolic syndrome with serum mineral status and kidney function in individuals with obesity.

Mokhtari Ardekani A, Nava Z, Zaman B, Vahdat S, Lame-Jouybari A, Mivefroshan A BMC Res Notes. 2023; 16(1):196.

PMID: 37670399 PMC: 10481520. DOI: 10.1186/s13104-023-06472-2.

References

El-Sayed Moustafa J, Froguel P . From obesity genetics to the future of personalized obesity therapy. Nat Rev Endocrinol. 2013; 9(7):402-13. DOI: 10.1038/nrendo.2013.57. View

de Oliveira A, Cruz K, Morais J, Severo J, de Freitas T, Veras A . Magnesium Status and Its Relationship with C-Reactive Protein in Obese Women. Biol Trace Elem Res. 2015; 168(2):296-302. DOI: 10.1007/s12011-015-0358-8. View

Mika A, Sledzinski T . Alterations of specific lipid groups in serum of obese humans: a review. Obes Rev. 2016; 18(2):247-272. DOI: 10.1111/obr.12475. View

Manjunath C, Rawal J, Irani P, Madhu K . Atherogenic dyslipidemia. Indian J Endocrinol Metab. 2014; 17(6):969-76. PMC: 3872713. DOI: 10.4103/2230-8210.122600. View

Misra A, Shrivastava U . Obesity and dyslipidemia in South Asians. Nutrients. 2013; 5(7):2708-33. PMC: 3738996. DOI: 10.3390/nu5072708. View

Cruz K, de Oliveira A, Pinto D, Morais J, da Silva Lima F, Colli C . Influence of magnesium on insulin resistance in obese women. Biol Trace Elem Res. 2014; 160(3):305-10. DOI: 10.1007/s12011-014-0044-2. View

Lefebvre P, Letois F, Sultan A, Nocca D, Mura T, Galtier F . Nutrient deficiencies in patients with obesity considering bariatric surgery: a cross-sectional study. Surg Obes Relat Dis. 2014; 10(3):540-6. DOI: 10.1016/j.soard.2013.10.003. View

Suliburska J, Cofta S, Gajewska E, Kalmus G, Sobieska M, Samborski W . The evaluation of selected serum mineral concentrations and their association with insulin resistance in obese adolescents. Eur Rev Med Pharmacol Sci. 2013; 17(17):2396-400. View

de Oliveira A, Cruz K, Severo J, Morais J, de Freitas T, Araujo R . Hypomagnesemia and its relation with chronic low-grade inflammation in obesity. Rev Assoc Med Bras (1992). 2017; 63(2):156-163. DOI: 10.1590/1806-9282.63.02.156. View

10.

Simental-Mendia L, Simental-Mendia M, Sahebkar A, Rodriguez-Moran M, Guerrero-Romero F . Effect of magnesium supplementation on lipid profile: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2017; 73(5):525-536. DOI: 10.1007/s00228-017-2212-8. View

11.

Rotter I, Kosik-Bogacka D, Dolegowska B, Safranow K, Karakiewicz B, Laszczynska M . Relationship between serum magnesium concentration and metabolic and hormonal disorders in middle-aged and older men. Magnes Res. 2015; 28(3):99-107. DOI: 10.1684/mrh.2015.0391. View

12.

Klop B, Elte J, Cabezas M . Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013; 5(4):1218-40. PMC: 3705344. DOI: 10.3390/nu5041218. View

13.

Guptha S, Gupta R, Deedwania P, Bhansali A, Maheshwari A, Gupta A . Cholesterol lipoproteins and prevalence of dyslipidemias in urban Asian Indians: a cross sectional study. Indian Heart J. 2014; 66(3):280-8. PMC: 4121768. DOI: 10.1016/j.ihj.2014.03.005. View

14.

Elmaogullari S, Tepe D, Ucakturk S, Kara F, Demirel F . Prevalence of Dyslipidemia and Associated Factors in Obese Children and Adolescents. J Clin Res Pediatr Endocrinol. 2016; 7(3):228-34. PMC: 4677559. DOI: 10.4274/jcrpe.1867. View

15.

Attane C, Peyot M, Lussier R, Poursharifi P, Zhao S, Zhang D . A beta cell ATGL-lipolysis/adipose tissue axis controls energy homeostasis and body weight via insulin secretion in mice. Diabetologia. 2016; 59(12):2654-2663. PMC: 6518076. DOI: 10.1007/s00125-016-4105-2. View

16.

Jung U, Choi M . Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014; 15(4):6184-223. PMC: 4013623. DOI: 10.3390/ijms15046184. View

17.

Schweiger M, Romauch M, Schreiber R, Grabner G, Hutter S, Kotzbeck P . Pharmacological inhibition of adipose triglyceride lipase corrects high-fat diet-induced insulin resistance and hepatosteatosis in mice. Nat Commun. 2017; 8:14859. PMC: 5364409. DOI: 10.1038/ncomms14859. View

18.

Wajchenberg B . Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2001; 21(6):697-738. DOI: 10.1210/edrv.21.6.0415. View

19.

Roberts R, Hodson L, Dennis A, Neville M, Humphreys S, Harnden K . Markers of de novo lipogenesis in adipose tissue: associations with small adipocytes and insulin sensitivity in humans. Diabetologia. 2009; 52(5):882-90. DOI: 10.1007/s00125-009-1300-4. View

20.

Scherer T, Lindtner C, Zielinski E, OHare J, Filatova N, Buettner C . Short term voluntary overfeeding disrupts brain insulin control of adipose tissue lipolysis. J Biol Chem. 2012; 287(39):33061-9. PMC: 3463338. DOI: 10.1074/jbc.M111.307348. View